Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease

Biological Psychiatry

Volumn 64, Issue 10, 2008, Pages 871-879

  Devanand, Davangere P ^a   Liu, Xinhua ^c   Tabert, Matthias H ^a   Pradhaban, Gnanavalli ^a   Cuasay, Katrina ^a   Bell, Karen ^b   de Leon, Mony J ^d   Doty, Richard L ^e   Stern, Yaakov ^a,b   Pelton, Gregory H ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; early markers; functional impairment; mild cognitive impairment; MRI medial temporal lobe atrophy; olfaction

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; ENTORHINAL CORTEX; FEMALE; GENOTYPE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HIPPOCAMPUS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC;

EID: 54149086289     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.06.020     Document Type: Article

References (41)

1. Di Carlo A., Lamassa M., Baldereschi M., Inzitari M., Scafato E., Farchi G., and Inzitari D. CIND and MCI in the Italian elderly: Frequency, vascular risk factors, progression to dementia. Neurology 68 (2007) 1909-1916
2. Larrieu S., Letenneur L., Orgogozo J.M., Fabrigoule C., Amieva H., Le Carret N., et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59 (2002) 1594-1599
3. Petersen R.C. Mild cognitive impairment: Current research and clinical implications. Semin Neurol 27 (2007) 22-31
4. Lopez O.L., Jagust W.J., DeKosky S.T., Becker J.T., Fitzpatrick A., Dulberg C., et al. Prevalence and classification of mild cognitive impairment in the Cardiovascular Health Study Cognition Study. Part 1. Arch Neurol 60 (2003) 1385-1389
5. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., et al. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256 (2004) 240-246
6. Devanand D.P., Michaels-Marston K.S., Liu X., Pelton G.H., Padilla M., Marder K., et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. Am J Psychiatry 157 (2000) 1399-1405
7. Tabert M.H., Liu X., Doty R.L., Serby M., Zamora D., Pelton G.H., et al. A 10-item smell identification scale related to risk for Alzheimer's disease. Ann Neurol 58 (2005) 155-160
8. Tabert M.H., Albert S.M., Borukhova-Milov L., Camacho Y., Pelton G., Liu X., et al. Functional deficits in patients with mild cognitive impairment: Prediction of AD. Neurology 58 (2002) 758-764
9. Graves A.B., Bowen J.D., Rajaram L., McCormick W.C., McCurry S.M., Schellenberg G.D., et al. Impaired olfaction as a marker for cognitive decline: Interaction with apolipoprotein E epsilon4 status. Neurology 53 (1999) 1480-1487
10. Portet F., Ousset P.J., Visser P.J., Frisoni G.B., Nobili F., Scheltens P., et al. Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 77 (2006) 714-718
11. Tabert M.H., Manly J.J., Liu X., Pelton G.H., Rosenblum S., Jacobs M., et al. Neuropsychological prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment. Arch Gen Psychiatry 63 (2006) 916-924
12. Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., et al. Hippocampal and entorhinal atrophy in the prediction of MCI conversion to Alzheimer's disease. Neurology 68 (2007) 828-836
13. Fleisher A.S., Sowell B.B., Taylor C., Gamst A.C., Petersen R.C., and Thal L.J. Alzheimer's Disease Cooperative Study. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 68 (2007) 1588-1595
14. Stoub T.R., Bulgakova M., Leurgans S., Bennett D.A., Fleischman D., Turner D.A., and deToledo-Morrell L. MRI predictors of risk of incident Alzheimer disease: A longitudinal study. Neurology 64 (2005) 1520-1524
15. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
16. Stern Y., Hesdorffer D., Sano M., and Mayeux R. Measurement and prediction of functional capacity in Alzheimer's disease. Neurology 40 (1990) 8-14
17. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., and Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56 (1999) 303-308
18. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer Disease. Neurology 34 (1984) 939-944
19. Devanand D.P., Pelton G.H., Zamora D., Liu X., Tabert M.H., Goodkind M., et al. Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. Arch Neurol 62 (2005) 975-980
20. Doty R.L., Shaman P., and Dann M. Development of the University of Pennsylvania Smell Identification Test: A standardized microencapsulated test of olfactory function. Physiol Behav 32 (1984) 489-502
21. Pfeffer R.I., Kurosaki T.T., Harrah Jr. C.H., Chance J.M., and Filos S. Measurement of functional activities in older adults in the community. J Gerontol 37 (1982) 323-329
22. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 22 (2001) 529-539
23. Killiany R.J., Hyman B.T., Gomez-Isla T., Moss M.B., Kikinis R., Jolesz F., et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 58 (2002) 1188-1196
24. Frye R.E., Schwartz B.S., and Doty R. Dose-related effects of cigarette smoking on olfactory function. JAMA 263 (1990) 1233-1236
25. Hastie T., Tibshirani R., and Friedman J. The Elements of Statistical Learning (2001), Springer Publishing Company, New York
26. Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Tsuda T., Chi H., et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 46 (1996) 149-154
27. Visser P.J., Verhey F.R., Scheltens P., Cruts M., Ponds R.W., Van Broeckhoven C.L., and Jolles J. Diagnostic accuracy of the Preclinical AD Scale (PAS) in cognitively mildly impaired subjects. J Neurol 249 (2002) 312-319
28. Mayeux R., Saunders A.M., Shea S., Mirra S., Evans D., Roses A.D., et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 338 (1998) 506-511
29. Tervo S., Kivipelto M., Hänninen T., Vanhanen M., Hallikainen M., Mannermaa A., and Soininen H. Incidence and risk factors for mild cognitive impairment: A population-based three-year follow-up study of cognitively healthy elderly subjects. Dement Geriatr Cogn Disord 17 (2004) 196-203
30. Blacker D., Lee H., Muzikansky A., Martin E.C., Tanzi R., McArdle J.J., Moss M., and Albert M. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 64 (2007) 862-871
31. Tyas S.L., Salazar J.C., Snowdon D.A., Desrosiers M.F., Riley K.P., Mendiondo M.S., and Kryscio R.J. Transitions to mild cognitive impairments, dementia, and death: Findings from the Nun Study. Am J Epidemiol 165 (2007) 1231-1238
32. Frank R.A., Galasko D., Hampel H., Hardy J., de Leon M.J., Mehta P.D., et al. National Institute on Aging Biological Markers Working Group. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24 (2003) 521-536
33. Doty R.L., Shaman P., Applebaum S.L., Giberson R., Sikorsky L., and Rosenberg L. Smell identification ability: Changes with age. Science 226 (1984) 1441-1443
34. Braak H., and Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82 (1991) 239-259
35. van de Pol L.A., Korf E.S., van der Flier W.M., Fox N.C., Barkhof F., and Scheltens P. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 64 (2007) 1023-1028
36. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 286 (2001) 2120-2127
37. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355 (2006) 2652-2663
38. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004) 306-319
39. Engler H., Forsberg A., Almkvist O., Blomquist G., Larsson E., Savitcheva I., et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129 (2006) 2856-2866
40. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 5 (2006) 228-234
41. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13 (2007) 1359-1362